Doctor Noon CVD and Doctor Noon Funders from medical artificial intelligence (AI) company MediWhale have been introduced to Rome American Hospital, a subsidiary of Italian medical corporation NefroCenter.
Dr.Noon CVD is AI software that predicts the risk of future cardiovascular disease with a simple eye test. It shows similar prediction performance to the coronary artery calcification index based on cardiac CT, which is currently evaluated as the most accurate prediction test in cardiology. Dr.Noon Fundus is AI software that assists in the interpretation of ophthalmic diseases, and automatically detects ophthalmic diseases such as retinal abnormalities, glaucoma, and media opacity with high accuracy by analyzing retinal images.
Nephrocenter is a medical group focused on the health care of patients with metabolic and renal diseases. It operates over 100 hospitals throughout Italy and provides comprehensive support to patients throughout the entire treatment process, based on its expertise and extensive experience, to more than 60,000 diabetic patients every year. In addition, the American Hospital of Rome, under the Nephrocenter, is a general hospital with 160 beds and over 300 specialists, and is highly regarded in the Italian medical community for ensuring the best medical service at each stage of treatment by utilizing state-of-the-art medical equipment.
As prevention of cardiovascular and metabolic diseases is increasingly becoming an important task in the medical field and the need for effective early diagnosis solutions is increasing, the American Hospital of Rome announced that it plans to introduce Dr.Nun to more precisely evaluate the health status of patients with metabolic syndrome and strengthen early diagnosis.
Choi Tae-geun, CEO of MediWhale, said, “Doctor Noon has been introduced in major European countries and is establishing itself as a new paradigm for preventing cardiovascular and metabolic diseases, and we are seeing positive feedback in the field.” He added, “We will cooperate with various medical institutions in Europe to prove the effectiveness of Doctor Noon and expand innovation so that Korean original technology can become a global standard.”
- See more related articles
You must be logged in to post a comment.